Skip to content

FATE THERAPEUTICS INC: diluted earnings per share

Diluted earnings per share for FATE THERAPEUTICS INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.

All FATE THERAPEUTICS INC financial histories

What this measure means

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Exact concept: us-gaap:EarningsPerShareDiluted. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Basic earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

Fate Therapeutics' selected 2020 and 2021 observations use dollar losses in thousands and full share counts. Basic and diluted shares are equal because potential common shares are anti-dilutive in loss periods. The nominal-exercise-price prefunded warrants issued in January 2021 already enter basic EPS; they are not an extra dilution adjustment. The filing also displays 2022, which is outside these selected historical observations. Read the source filing.

Fate Therapeutics' 2024 and 2025 statements report dollar losses in thousands and full shares. Basic EPS already includes nominal-exercise-price prefunded warrants from the January 2021 and March 2024 financings. In 2025, 114,896,300 weighted-average common shares plus 3,893,674 weighted-average prefunded warrants produce the 118,789,974 denominator; in 2024, 110,596,272 plus 3,088,905 produce 113,685,177. Other potential common shares are excluded as anti-dilutive during losses. Year-end excluded securities are not additions to these weighted-average denominators. Read the source filing.

Selected filing history

Diluted earnings per share in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
2025-01-012025-12-31-1.15USD/shares2026-02-2610-K · 0001193125-26-073699
2024-01-012024-12-31-1.64USD/shares2026-02-2610-K · 0001193125-26-073699
2023-01-012023-12-31-1.64USD/shares2025-03-0510-K · 0000950170-25-033510
2022-01-012022-12-31-2.91USD/shares2024-02-2610-K · 0000950170-24-020158
2021-01-012021-12-31-2.24USD/shares2023-02-2810-K · 0000950170-23-005067
2020-01-012020-12-31-2.1USD/shares2023-02-2810-K · 0000950170-23-005067

Related financial histories

Inspect the source

Entity
FATE THERAPEUTICS INC / CIK 0001434316
Captured
2026-09-20T09:02:50.083Z
SEC response SHA-256
0d3cfe19fd70310e30c155481681c8ab78f983607cbe93ec4d5e89a1219f24a2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001434316.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))